Madison Elsaadi
Stock Analyst at B. Riley Securities
(4.49)
# 1,197
Out of 5,133 analysts
75
Total ratings
41.7%
Success rate
25.4%
Average return
Main Sectors:
Stocks Rated by Madison Elsaadi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Maintained: Buy | $21 | $11.22 | +87.17% | 9 | Nov 12, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $123 | $49.36 | +149.19% | 8 | Nov 10, 2026 | |
| ETON Eton Pharmaceuticals | Reiterated: Buy | $40 → $81 | $68.40 | +18.42% | 15 | Nov 10, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $160 | $46.20 | +246.32% | 2 | Nov 10, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $22 → $18 | $3.42 | +426.32% | 18 | Nov 9, 2026 | |
| STIM Neuronetics | Initiated Coverage: Buy | $5 → $6 | $1.62 | +270.37% | 2 | Nov 6, 2026 | |
| VNDA Vanda Pharmaceuticals | Reiterated: Buy | $12 | $4.15 | +189.16% | 7 | Oct 29, 2026 | |
| OBIO Orchestra BioMed Holdings | Reiterated: Buy | $11 | $6.01 | +83.03% | 2 | Oct 2, 2026 | |
| ANIK Anika Therapeutics | Initiated Coverage: Buy | $23 | $13.95 | +64.87% | 1 | Sep 18, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $17 → $22 | $9.30 | +136.56% | 2 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.78 | +79.86% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $10 | $4.31 | +132.02% | 2 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $16 | $10.64 | +50.38% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $179 | $149.24 | n/a | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $7.22 | n/a | 1 | Jan 23, 2025 |
Capricor Therapeutics
Nov 12, 2026
Maintained: Buy
Price Target: $21
Current: $11.22
Upside: +87.17%
Arrowhead Pharmaceuticals
Nov 10, 2026
Reiterated: Buy
Price Target: $123
Current: $49.36
Upside: +149.19%
Eton Pharmaceuticals
Nov 10, 2026
Reiterated: Buy
Price Target: $40 → $81
Current: $68.40
Upside: +18.42%
Spruce Biosciences
Nov 10, 2026
Reiterated: Buy
Price Target: $160
Current: $46.20
Upside: +246.32%
Wave Life Sciences
Nov 9, 2026
Reiterated: Buy
Price Target: $22 → $18
Current: $3.42
Upside: +426.32%
Neuronetics
Nov 6, 2026
Initiated Coverage: Buy
Price Target: $5 → $6
Current: $1.62
Upside: +270.37%
Vanda Pharmaceuticals
Oct 29, 2026
Reiterated: Buy
Price Target: $12
Current: $4.15
Upside: +189.16%
Orchestra BioMed Holdings
Oct 2, 2026
Reiterated: Buy
Price Target: $11
Current: $6.01
Upside: +83.03%
Anika Therapeutics
Sep 18, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $13.95
Upside: +64.87%
COMPASS Pathways
Aug 6, 2026
Reiterated: Buy
Price Target: $17 → $22
Current: $9.30
Upside: +136.56%
May 13, 2026
Reiterated: Buy
Price Target: $5
Current: $2.78
Upside: +79.86%
Apr 30, 2026
Reiterated: Buy
Price Target: $9 → $10
Current: $4.31
Upside: +132.02%
Feb 12, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $10.64
Upside: +50.38%
Oct 1, 2025
Initiated Coverage: Buy
Price Target: $179
Current: $149.24
Upside: n/a
Jan 23, 2025
Reiterated: Buy
Price Target: $11
Current: $7.22
Upside: n/a